IPO Market Shows Signs of Constipation

There are all kinds of puns one could make up about a company developing treatments for irritable bowel syndrome that just pulled off a somewhat disappointing initial public offering. For negative spin, one could talk about how no one seems able to unclog the life sciences IPO market. Or, for a more positive take, how a bowel company’s market debut, though priced below expectations, offers some signs of relief for the blocked-up pipeline of initial public offerings.

ManagersNorth AmericaUSBriefs